“After 3 years of painful underperformance, winter is finally thawing and spring just might be in the air... We favor names and are initially launching on cos with clear clinical narratives and/or commercial upside. We’ve got our hands in all the hot areas … oncology, neuro, rare, cardiometabolic, etc.”

 “We forecast strong earnings and cash flows for Regernon and highlighted its broad pipeline.”

 “No direct quote but included as part of The Magnificent Seven with an overweight rating.”

 “Rare diseases company Neurocrine also has meaningful catalysts ahead... its Huntington disease treatment Ingrezza’s growth and the investigational treatment crinecerfont’s ‘blockbuster potential’ have created a positive backdrop for Neurocrine.”

 “The market is settling back into the soft landing narrative after softer US jobs data and dovish guidance from the Fed, ECB and BoE.”